MX2017012829A - Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. - Google Patents
Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.Info
- Publication number
- MX2017012829A MX2017012829A MX2017012829A MX2017012829A MX2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A
- Authority
- MX
- Mexico
- Prior art keywords
- humanized
- mhc
- human
- cell
- correceptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143687P | 2015-04-06 | 2015-04-06 | |
| US201562158804P | 2015-05-08 | 2015-05-08 | |
| US201562186935P | 2015-06-30 | 2015-06-30 | |
| PCT/US2016/026260 WO2016164492A2 (en) | 2015-04-06 | 2016-04-06 | Humanized t cell mediated immune responses in non-human animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012829A true MX2017012829A (es) | 2018-02-23 |
Family
ID=56926255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012829A MX2017012829A (es) | 2015-04-06 | 2016-04-06 | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| MX2023002653A MX2023002653A (es) | 2015-04-06 | 2017-10-05 | Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002653A MX2023002653A (es) | 2015-04-06 | 2017-10-05 | Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11259510B2 (https=) |
| EP (2) | EP4248744A3 (https=) |
| JP (6) | JP6796597B2 (https=) |
| KR (2) | KR102699643B1 (https=) |
| CN (2) | CN107666828B (https=) |
| AU (3) | AU2016246698B2 (https=) |
| CA (2) | CA2980771C (https=) |
| DK (1) | DK3280257T3 (https=) |
| ES (1) | ES2954865T3 (https=) |
| FI (1) | FI3280257T3 (https=) |
| HR (1) | HRP20231039T1 (https=) |
| HU (1) | HUE064168T2 (https=) |
| IL (4) | IL318990A (https=) |
| LT (1) | LT3280257T (https=) |
| MX (2) | MX2017012829A (https=) |
| NZ (1) | NZ736031A (https=) |
| PL (1) | PL3280257T3 (https=) |
| PT (1) | PT3280257T (https=) |
| RS (1) | RS64540B1 (https=) |
| RU (1) | RU2732628C2 (https=) |
| SG (2) | SG10201909320UA (https=) |
| SI (1) | SI3280257T1 (https=) |
| SM (1) | SMT202300408T1 (https=) |
| WO (1) | WO2016164492A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900478T1 (it) | 2011-10-28 | 2019-09-09 | Regeneron Pharma | Topi con complesso maggiore di istocompatibilita' geneticamente modificati |
| SMT202200205T1 (it) | 2011-10-28 | 2022-07-21 | Regeneron Pharma | Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| CN107858333B (zh) | 2011-10-28 | 2022-05-27 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| CN111484999B (zh) | 2013-02-20 | 2024-10-25 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| EP3699190B9 (en) | 2013-02-22 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Murine cell expressing humanized major histocompatibility complex |
| WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| DK3422845T3 (da) | 2016-02-29 | 2021-08-30 | Regeneron Pharma | Gnavere med et humaniseret tmprss-gen |
| KR102483193B1 (ko) | 2016-06-03 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
| US20190098879A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
| KR20200075851A (ko) * | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| EP3940382B1 (en) | 2018-03-24 | 2024-07-03 | Regeneron Pharmaceuticals, Inc. | Methods for identifying hla-associated tumor peptides |
| IL314733A (en) | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| HRP20240999T1 (hr) | 2018-07-16 | 2024-10-25 | Regeneron Pharmaceuticals, Inc. | Glodavački modeli bolesti ditra i njihova upotreba |
| WO2020086647A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Ny-eso-1 t cell receptors and methods of use thereof |
| WO2020092839A1 (en) * | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| KR102661779B1 (ko) | 2019-04-04 | 2024-04-30 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 |
| SG11202111865UA (en) * | 2019-05-01 | 2021-11-29 | Pact Pharma Inc | Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| AU2020358975A1 (en) * | 2019-10-03 | 2022-04-21 | Regeneron Pharmaceuticals, Inc. | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells |
| EP4093753A1 (en) | 2020-01-24 | 2022-11-30 | Regeneron Pharmaceuticals, Inc. | Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof |
| CN118511853A (zh) | 2021-03-31 | 2024-08-20 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| WO2023092119A2 (en) | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
| CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
| CN115074368B (zh) * | 2022-06-09 | 2023-08-08 | 澳门科技大学 | 一种耐药型类风湿性关节炎动物模型的构建及其应用 |
| AU2023347224A1 (en) | 2022-09-22 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
| JP2026509947A (ja) | 2022-10-31 | 2026-03-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法 |
| WO2024112806A1 (en) * | 2022-11-21 | 2024-05-30 | Moonwalk Biosciences, Inc. | Generation and use of epigenetic maps for drug discovery |
| CN120882754A (zh) | 2023-04-07 | 2025-10-31 | 瑞泽恩制药公司 | 用淋巴毒素β受体激动剂治疗癌症的方法 |
| EP4720109A1 (en) | 2023-05-25 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958678A (en) | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| JPH04501510A (ja) | 1989-07-25 | 1992-03-19 | セル ジェネシス，インコーポレイティド | 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| CA2246333A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| CA2302779C (en) | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| AU1023401A (en) | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7462486B2 (en) | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| WO2002000933A2 (en) | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
| US6911204B2 (en) * | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002047474A1 (en) | 2000-12-13 | 2002-06-20 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| IL160359A0 (en) * | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| EP1452093A4 (en) | 2001-11-15 | 2007-08-15 | Kirin Brewery | CHIMESE NON-MENTAL ANIMAL |
| JP4238138B2 (ja) | 2001-12-22 | 2009-03-11 | ４−アンチボディ アーゲー | 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。 |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| US20060156419A1 (en) | 2002-10-30 | 2006-07-13 | The Wistar Institute Of Anatomy And Biology | Mouse model for autoimmune disorders |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US7745690B2 (en) | 2004-03-09 | 2010-06-29 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| CN101534859B (zh) * | 2006-09-08 | 2017-06-09 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| US9388425B2 (en) | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠 |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| WO2010107400A1 (en) | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US9695410B2 (en) | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
| US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| CN103348012B (zh) | 2010-11-27 | 2016-06-08 | 朱坚 | 一种人源化的转基因动物 |
| CN108866101A (zh) | 2011-10-28 | 2018-11-23 | 瑞泽恩制药公司 | 人源化il-6和il-6受体 |
| CN107858333B (zh) * | 2011-10-28 | 2022-05-27 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| SMT202200205T1 (it) | 2011-10-28 | 2022-07-21 | Regeneron Pharma | Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii |
| SMT201900478T1 (it) | 2011-10-28 | 2019-09-09 | Regeneron Pharma | Topi con complesso maggiore di istocompatibilita' geneticamente modificati |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| CN111484999B (zh) * | 2013-02-20 | 2024-10-25 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| EP3699190B9 (en) | 2013-02-22 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Murine cell expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA2902543A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| JP6456350B2 (ja) | 2013-03-11 | 2019-01-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス |
-
2016
- 2016-04-06 EP EP23175865.7A patent/EP4248744A3/en active Pending
- 2016-04-06 CA CA2980771A patent/CA2980771C/en active Active
- 2016-04-06 CA CA3223798A patent/CA3223798A1/en active Pending
- 2016-04-06 SG SG10201909320U patent/SG10201909320UA/en unknown
- 2016-04-06 HR HRP20231039TT patent/HRP20231039T1/hr unknown
- 2016-04-06 HU HUE16766106A patent/HUE064168T2/hu unknown
- 2016-04-06 MX MX2017012829A patent/MX2017012829A/es unknown
- 2016-04-06 WO PCT/US2016/026260 patent/WO2016164492A2/en not_active Ceased
- 2016-04-06 RU RU2017137786A patent/RU2732628C2/ru active
- 2016-04-06 EP EP16766106.5A patent/EP3280257B1/en active Active
- 2016-04-06 IL IL318990A patent/IL318990A/en unknown
- 2016-04-06 RS RS20230771A patent/RS64540B1/sr unknown
- 2016-04-06 DK DK16766106.5T patent/DK3280257T3/da active
- 2016-04-06 NZ NZ736031A patent/NZ736031A/en unknown
- 2016-04-06 CN CN201680030625.XA patent/CN107666828B/zh active Active
- 2016-04-06 KR KR1020177032048A patent/KR102699643B1/ko active Active
- 2016-04-06 KR KR1020247028283A patent/KR20240132525A/ko active Pending
- 2016-04-06 ES ES16766106T patent/ES2954865T3/es active Active
- 2016-04-06 FI FIEP16766106.5T patent/FI3280257T3/fi active
- 2016-04-06 CN CN202110308348.7A patent/CN113349159B/zh active Active
- 2016-04-06 IL IL284809A patent/IL284809B2/en unknown
- 2016-04-06 US US15/564,723 patent/US11259510B2/en active Active
- 2016-04-06 PL PL16766106.5T patent/PL3280257T3/pl unknown
- 2016-04-06 SM SM20230408T patent/SMT202300408T1/it unknown
- 2016-04-06 SG SG11201707691WA patent/SG11201707691WA/en unknown
- 2016-04-06 PT PT167661065T patent/PT3280257T/pt unknown
- 2016-04-06 SI SI201631742T patent/SI3280257T1/sl unknown
- 2016-04-06 JP JP2017552483A patent/JP6796597B2/ja active Active
- 2016-04-06 LT LTEPPCT/US2016/026260T patent/LT3280257T/lt unknown
- 2016-04-06 AU AU2016246698A patent/AU2016246698B2/en active Active
- 2016-04-06 IL IL297097A patent/IL297097B2/en unknown
-
2017
- 2017-09-28 IL IL254775A patent/IL254775A0/en unknown
- 2017-10-05 MX MX2023002653A patent/MX2023002653A/es unknown
-
2020
- 2020-05-14 JP JP2020085069A patent/JP2020115896A/ja not_active Withdrawn
-
2022
- 2022-01-13 US US17/575,450 patent/US20220174921A1/en active Pending
- 2022-08-01 JP JP2022122754A patent/JP2022140609A/ja not_active Withdrawn
- 2022-08-26 AU AU2022221563A patent/AU2022221563B2/en active Active
-
2023
- 2023-10-18 JP JP2023179453A patent/JP7763820B2/ja active Active
-
2024
- 2024-07-17 JP JP2024114035A patent/JP7555515B1/ja active Active
-
2025
- 2025-05-06 AU AU2025203245A patent/AU2025203245A1/en active Pending
- 2025-10-22 JP JP2025177694A patent/JP2026009189A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012829A (es) | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. | |
| CY1125424T1 (el) | Μη-ανθρωπινα ζωα που εκφραζουν ανθρωποποιημενο cd3 συμπλοκο | |
| BR112023018874A2 (pt) | Camundongos geneticamente modificados compreendendo componentes do sistema imunológico celular humanizado com diversidade melhorada do repertório de tcrb | |
| Petersdorf | Genetics of graft-versus-host disease: the major histocompatibility complex | |
| WO2014130671A8 (en) | Mice expressing humanized t-cell co-receptors | |
| NZ736031A9 (en) | Humanized t cell mediated immune responses in non-human animals | |
| EP4311833A3 (en) | Genetically modified major histocompatibility complex mice | |
| CY1120945T1 (el) | Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων | |
| MX2017009459A (es) | Célula t asesina universal. | |
| UY36471A (es) | Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim) | |
| MX373286B (es) | Roedores humanizados que expresan cadenas pesadas que contienen dominios vl. | |
| MX2016013158A (es) | Productos de celulas t modificadas de genes de composicion definida. | |
| MX2019006734A (es) | Sistemas y metodos para secuenciar receptores de linfocitos t, y usos de estos. | |
| SG10201909638UA (en) | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules | |
| MX2019011514A (es) | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. | |
| MX2022001202A (es) | Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos. | |
| CU24437B1 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| CY1117606T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
| MX370148B (es) | Composiciones y su uso para inmunoterapia. | |
| MX2017002459A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
| EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
| BR112019021857A2 (pt) | Métodos e composições de célula t aperfeiçoada | |
| BR112021018788A2 (pt) | Células, tecidos e órgãos personalizados para transplante de um doador (não humano) humanizado, indivi-dualizado, designado livre de patógenos e métodos e produtos relacionados aos mesmos | |
| RU2019140867A (ru) | Nsg мыши, не имеющие mhc класса i и класса ii | |
| AR116048A1 (es) | Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión |